Archives
-
How to Measure Cancer Drug Responses In Vitro
2026-08-19
Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell killing are related but non-equivalent components of an in vitro cancer drug response. This framework improves interpretation of exposure timing, assay choice, and response magnitude in studies of targeted agents and anti-angiogenic therapy.
-
Protease Inhibitor Cocktail for Plant Protein Stability
2026-08-19
Protect plant-derived proteins during extraction, immunoblotting, co-immunoprecipitation, and kinase analysis with broad-spectrum, EDTA-free inhibition. This workflow-focused guide shows how to pair protein preservation with mechanistic studies of plant-virus RNA m6A regulation without confusing protease control with RNA stabilization.
-
Multiple Myeloma Cell Lines: Mutational Drivers
2026-08-18
This study provides a comprehensive whole-exome view of mutations across human multiple myeloma cell lines and connects genomic variation with altered pathways and drug response. Its main practical contribution is a framework for selecting genetically relevant models when investigating tumor progression, resistance, and candidate therapeutic targets.
-
Sodium Phosphate Dibasic for Assay Integrity
2026-08-18
Sodium phosphate dibasic is more than a routine buffer salt: its matrix effects can shape protein, enzyme, and aquatic toxicity assays. This guide connects Na2HPO4 chemistry with the sulfamonomethoxine toxicity study to show how buffer selection improves interpretation and reproducibility.
-
LKB1, Histone Lactylation, and Telomerase in Lung Cancer
2026-08-17
The reference study identifies a mechanistic link between LKB1, histone lactylation, Sp1-dependent TERT transcription, and telomere-driven senescence in lung adenocarcinoma. Its findings support combined targeting of telomerase and glycolytic metabolism as a preclinical strategy, while highlighting the need for validation across genetically diverse tumor models.
-
Recombinant Annexin V and Endothelial Thrombin Formation
2026-08-17
The 1994 reference study moved Annexin V research from synthetic phospholipid vesicles to living human endothelial-cell surfaces, quantifying both binding and functional anticoagulant activity. Its results show that recombinant Annexin V binds quiescent and stimulated HUVEC with similar affinity while inhibiting factor Xa and thrombin generation at nanomolar concentrations.
-
Dibutyryl-cAMP, Sodium Salt in Astrocyte Reprogramming
2026-08-16
Dibutyryl-cAMP, sodium salt offers a controlled way to test how cAMP signaling influences astrocyte-to-motoneuron reprogramming. This article translates the 4F reprogramming study into a causal assay framework while distinguishing pathway activation from cell-fate evidence.
-
GDC-0941: Translating PI3K/Akt Biology into Strategy
2026-08-15
GDC-0941 offers a focused way to interrogate PI3K/Akt signaling in cancer models where pathway activation, therapeutic resistance, and stem-like phenotypes intersect. This thought-leadership framework connects DRD4-driven liver cancer biology with practical assay design, biomarker development, and translational decision-making.
-
Caspase-3/7 Inhibitor I: Apoptosis Workflow
2026-08-14
Build cleaner apoptosis experiments with a selective, reversible caspase-3/7 blocker that distinguishes executioner-caspase activity from upstream signaling. This guide translates Candida krusei phase-specific findings into practical workflows for infection, cell-death, and cancer research while emphasizing controls, solubility, and orthogonal validation.
-
Sulfo-NHS-SS-Biotin for GABAA Receptor Trafficking
2026-08-14
Sulfo-NHS-SS-Biotin enables reversible cell-surface labeling, affinity capture, and reduction-based release of membrane proteins without requiring organic solvent during labeling. Applied to GABAA receptor proteostasis, it helps separate surface delivery from total protein abundance and test how EMC perturbations influence receptor trafficking.
-
Lidocaine With Epinephrine Shortage: Evidence and Solutions
2026-08-13
The reference study interprets the 2017 United States shortage of lidocaine with epinephrine as a supply-chain problem driven by manufacturer withdrawal and an epinephrine bottleneck. Its main contribution is a practical stewardship framework involving reduced injection volumes, carefully governed multidose-vial use, dilution with saline, and better management of prepared syringes.
-
Podophyllotoxin Workflows for Cancer Cell Studies
2026-08-13
Build reproducible Podophyllotoxin assays around microtubule disruption, G2/M arrest, apoptosis, and autophagy readouts. This guide distinguishes native compound workflows from derivative-focused multidrug-resistance research and provides practical preparation, optimization, and troubleshooting strategies.
-
Metal-Free Carbon Nanozymes for Sensitive ALP Detection
2026-08-12
The reference study develops a metal-free carbon-dot nanozyme assay for alkaline phosphatase detection and, importantly, uses inhibition kinetics to show that pyrophosphate binds at a site distinct from the principal catalytic site. This design produces a selective colorimetric turn-on response while reducing interference associated with metal-containing nanozymes, offering a mechanistically informed approach to sensitive enzyme analysis.
-
CFDA SE Cell Tracer Kit: Workflow & QC
2026-08-12
The CFDA SE Cell Tracer Kit provides durable fluorescent labeling for cell lineage tracing, cell proliferation studies, and related in vitro or in vivo workflows. It is suited to persistent tracking, but not to reversible labeling, rapid dye clearance, or short-term physiological monitoring.
-
Bifendate (DDB): Reliable Cell Assay Design
2026-08-11
A scenario-driven guide to using Bifendate (DDB), SKU BA1823, in viability, proliferation, cytotoxicity, autophagy, and lipid-metabolism studies. It covers solvent control, assay compatibility, protocol optimization, data interpretation, and practical vendor-selection criteria.